Inhibition of p38 MAPK diminishes doxorubicin- induced drug resistance associated with P-glycoprotein in human leukemia K562 cells

Medical Science Monitor

Volumn 18, Issue 10, 2012, Pages

  Chen, Yinghui ^a   Zhao, Yongbo ^b   Wang, Cuicui ^a   Xiao, Xia ^a   Zhou, Xiaoyong ^a   Xu, Guoxiong ^a  

^a FUDAN UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cancer; Doxorubicin; Drug resistance; P glycoprotein; P38 MAPK

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYTOKERATIN 8; DOXORUBICIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PHENYTOIN;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; GENE OVEREXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; IMMUNOCYTOCHEMISTRY; LEUKEMIA CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING; WILD TYPE;

EID: 84867617641     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883477     Document Type: Article

References (32)

1. Zarubin T, Han J: Activation and signaling of the p38 MAP kinase path-way Cell Res, 2005; 15: 11-18
2. Wagner EF, Nebreda AR: Signal integration by JNK and p38 MAPK path-ways in cancer development. Nat Rev Cancer, 2009; 9: 537-49
3. Rajkumar T, Yamuna M: Multiple pathways are involved in drug resis-tance to doxorubicin in an osteosarcoma cell line. Anticancer Drugs, 2008; 19: 257-65
4. Peetla C, Bhave R, Vijayaraghavalu S et al: Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids. Mol Pharm, 2010; 7: 2334-48
5. Hemauer SJ, Nanovskaya TN, Abdel-Rahman SZ et al: Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. Biochem Pharmacol, 2010; 79: 921-25
6. Chengyun D, Guoming L, Elia M et al: Expression of multidrug resistance type 1gene (MDR1) P-glycoprotein in intractable epilepsy with different aetiologies: a double-labelling and electron microscopy study. Neurol Sci, 2006; 27: 245-51
7. Kubota H, Ishihara H, Langmann T et al: Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res, 2006; 68: 213-28
8. Baguley BC: Multiple drug resistance mechanisms in cancer. Mol Biotechnol, 2010; 46: 308-16
9. Loscher W, Langer O: Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy. Curr Top Med Chem, 2010; 10: 1785-91
10. Lazarowski A, Czornyj L, Lubienieki F et al: ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia, 2007; 48(Suppl.5): 140-49
11. Hong H, Lu Y, Ji ZN, Liu GQ: Up-regulation of P-glycoprotein expression by glutathione depletion-induced oxidative stress in rat brain microvessel endothelial cells. J Neurochem, 2006; 98: 1465-73
12. Sukhai M, Piquette-Miller M: Regulation of the multidrug resistance genes by stress signals. J Pharm Pharm Sci, 2000; 3: 268-80
13. Ho EA, Piquette-Miller M: Regulation of multidrug resistance by proinflammatory cytokines. Curr Cancer Drug Targets, 2006; 6: 295-311
14. Coulthard LR, White DE, Jones DL et al: p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med, 2009; 15: 369-79
15. Hur JM, Hyun MS, Lim SY et al: The combination of berberine and irradiation enhances anti-cancer effects via activation of p38 MAPK pathway and ROS generation in human hepatoma cells. J Cell Biochem,2009; 107: 955-64
16. Koizumi K, Tanno S, Nakano Y et al: Activation of p38 mitogen-activated protein kinase is necessary for gemcitabine-induced cytotoxicity in human pancreatic cancer cells. Anticancer Res, 2005; 25: 3347-53
17. Mahon FX, Hayette S, Lagarde V et al: Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.Cancer Res, 2008; 68: 9809-16
18. Potschka H, Fedrowitz M, Loscher W: P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport, 2001; 12: 3557-60
19. Li Y, Yuan H, Yang K et al: The structure and functions of P-glycoprotein. Curr Med Chem, 2010; 17: 786-800
20. Borst P, Evers R, Kool M, Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst, 2000; 92: 1295-1302
21. Kuranaga N, Shinomiya N, Mochizuki H: Long-term cultivation of colorectal carcinoma cells with anti-cancer drugs induces drug resistance and telomere elongation: an in vitro study. BMC Cancer, 2001; 1: 10
22. Zwang Y, Yarden Y: p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. Embo J, 2006; 25: 4195-206
23. Park HJ, Han ES, Park DK: The ethyl acetate extract of PGP (Phellinus inteus grown on Panax ginseng) suppresses B16F10 melanoma cell proliferation through inducing cellular differentiation and apoptosis. J Ethnopharmacol, 2010; 132: 115-21
24. Bu SZ, Huang Q, Jiang YM et al: p38 Mitogen-activated protein kinases is required for counteraction of 2-methoxyestradiol to estradiol-stimulated cell proliferation and induction of apoptosis in ovarian carcinoma cells via phosphorylation Bcl-2. Apoptosis, 2006; 11: 413-25
25. Guo X, Ma N, Wang J et al: Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer, 2008; 8: 375
26. Duncia JV, Santella III JB, Higley CA et al: MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg Med Chem Lett, 1998; 8: 2839-44
27. Katayama K, Yoshioka S, Tsukahara S et al: Inhibition of the mitogen activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther, 2007; 6: 2092-102
28. Favata MF, Horiuchi KY, Manos EJ et al: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem, 1998; 273:18623-32
29. Nemoto S, Xiang J, Huang S, Lin A: Induction of apoptosis by SB202190 through inhibition of p38beta mitogen-activated protein kinase. J Biol Chem, 1998; 273: 16415-20
30. Sauvant C, Nowak M, Wirth C et al: Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38. Int J Cancer, 2008; 123: 2532-42
31. Bentires-Alj M, Barbu V, Fillet M et al: NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene, 2003; 22: 90-97
32. Saha RN, Jana M, Pahan K: MAPK p38 regulates transcriptional activity of NF-kappaB in primary human astrocytes via acetylation of p65. J Immunol, 2007; 179: 7101-9